Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP2045 |
CH 275
|
||
Potent somatostatin receptor 1 (sst1) agonist; displays selectivity for sst1 (IC50 values are 30.9 nM, 345 nM, > 1 μM, > 10 μM and > 10μM for human sst1, sst3, sst4, sst2 and sst5 respectively). Attenuates somatostatin release in the rat nucleus accumbens | |||
TP2135 |
cAC 253
|
||
Amylin (AMY3) antagonist (IC50 = 0.3 μM). Protects neuronal cells from Aβ(1-42)-induced cytotoxicity in vitro. Brain penetrant. Improves spatial memory and reduces Aβ plaque number and total area in a mouse Alzheimer's disease model. | |||
T69664 |
Umibecestat HCl
|
||
Umibecestat, also known as CNP-520, is a beta-secretase inhibitor and is a drug candidate for prevention trials in Alzheimer's disease. CNP520 has a selectivity, pharmacodynamics, and distribution profile suitable for AD prevention studies. CNP520 reduced brain and cerebrospinal fluid (CSF) Aβ in rats and dogs, and Aβ plaque deposition in APP-transgenic mice. CNP520 reduces Aβ load and neuroinflammation in APP‐transgenic mice |